You are here

Novel Medical Countermeasures for Opioid Intoxication

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-20-P-0037
Agency Tracking Number: C192-008-0052
Amount: $167,351.40
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD192-008
Solicitation Number: 19.2
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-04-03
Award End Date (Contract End Date): 2020-09-03
Small Business Information
737 Concord Ave
Cambridge, MA 02138
United States
DUNS: 080316838
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Xinhua Li
 EVP Chemistry
 (617) 621-8500
Business Contact
 Peter Howe
Phone: (617) 621-8500
Research Institution

Synthetic opioids including fentanyl and its derivatives pose a serious threat to both civilians and warfighters. The serum half-life of the current FDA-approved antidote for acute opioid poisoning, naloxone, is shorter than that for fentanyl and its synthetic analogs, and thus does not provide effective protection against these threat agents. The mechanism of action of naloxone is by competitive antagonism at μ-opioid receptors in the central and peripheral nerve systems. Not surprisingly, renarcotization is known to occur as the effect of naloxone dissipates, as fentanyl(s) clearance from the body is relatively slow, and multiple doses of naloxone are often required. We propose to develop a novel class of medical countermeasures that address the drawbacks of naloxone via a different mechanism of action, thus providing improved treatment for both immediate rescue and prolonged protection without renarcotization. The novel medical countermeasure will also allow the use of current opioid-based protocols for pain management.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government